Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11; 116(19):3758-65.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Antineoplastic Agents
Benzamides
Disease-Free Survival
Female
Genes, abl
Humans
Imatinib Mesylate
Interferons
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Piperazines
Prognosis
Pyrimidines
Remission Induction
Time Factors
Treatment Outcome
Young Adult

authors with profiles

Richard A. Larson